The Duke Cancer Institute (DCI) wants to assure our patients that the safety of our patients, their loved ones, our team members and the community at large remains our highest priority. We are closely monitoring this rapidly evolving situation and are implementing all necessary precautions to prevent the spread of infection.

For the latest information about how we are keeping our community safe, please visit www.dukehealth.org.

Urinary Bladder

Urinary Bladder

4 items identified

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy

Wrist accelerometry for assessing perioperative physical activity in subjects undergoing bladder surgery

Phase II Single Arm Study of Gemcitabine and Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies